Cullinan Management, Inc. ( ($CGEM) ) has released its Q1 earnings. Here is a breakdown of the information Cullinan Management, Inc. presented to ...

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 78 cents per share. Cullinan Therapeutics shares have fallen 37% ...

NASDAQ:CGEM opened at $7.89 on Wednesday. The firm has a market capitalization of $461.67 million, a P/E ratio of -2.78 and a beta of -0.05. The company has a fifty day moving average of $8.40 and ...

Cullinan Therapeutics (CGEM) announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer patients with EGFR ...

As a leader in T cell engager development for autoimmune diseases, we continue to rapidly advance our global clinical development of CLN-978 in ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Cullinan Therapeutics (CGEM) closed the last trading session at $8.28, gaining 5.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Cullinan Therapeutics, Inc. (CGEM) on Thursday reported a loss of $48.5 million in its first quarter. The Cambridge, Massachusetts-based company ...

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 292.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...